09/18/2025 | News release | Distributed by Public on 09/18/2025 13:30
2025 Avis Professorship: Howard Gendelman, MD | Reaching an Effective Immunotherapy for Alzheimer's Disease
October 30, 1:00 - 2:00 pm | Pharmacy Building, Room 102
'A Presentation in the UTHSC Distinguished Lecture Series on Drug Discovery & Development'
Join the Department of Pharmaceutical Sciences for the 2025 Avis Professorship Presentation featuring this year's recipient, Howard E. Gendelman, MD., Margaret R. Larson Professor of Internal Medicine and Infectious Diseases and Chair, UNMC Department of Pharmacology and Experimental Neuroscience at College of Medicine, University of Nebraska Medical Center.
Sponsored by The Kenneth E. Avis Distinguished Visiting Professorship Endowment.
Lecture: Reaching an Effective Immunotherapy for Alzheimer's Disease
Effective therapies that target the root cause for neurodegenerative diseases have not been achieved. Combinatorial immunotherapies were developed that improve neuronal integrity and ameliorate disease signs linked to associated pathologies were achieved. They require fully characterized models for theranostic tests. Each were realized in model systems tested by noninvasive bioimaging. Confirmation were made by neuropathology, neural communication, neuroimmunity, and pharmacologic testing. Each are operative for human translation. Human cross-relevant validations were explored for how Alzheimer's disease immunotherapies can improve deficits in synaptic structures, function, neurotransmission; blood-brain barrier integrity, and neuroinflammation (both brain-infiltrating immunocytes and resident innate immune function). All were merged with studies of cognitive functions, oxidative and metabolic stress, and cellular senescence. Our newly developed humanized APP/PS1/Tau knock CRISPR mouse allowed translational studies of human immune responses during disease. The success of developmental immune-based therapeutics will be discussed.
More information can be found here.